Park M - Search Results

1

Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review.

Anderson-Smits C, Park M, Bell J, Mitchell S, Hartley L, Hawe E. Anderson-Smits C, et al. Among authors: park m. Immunotherapy. 2022 Apr;14(5):373-387. doi: 10.2217/imt-2021-0265. Epub 2022 Feb 7. Immunotherapy. 2022. PMID: 35128932 Review.

2

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.

Fasshauer M, Borte M, Bitzenhofer M, Pausch C, Pittrow D, Park M, Gladiator A, Jandus P. Fasshauer M, et al. Among authors: park m. Adv Ther. 2023 Dec;40(12):5168-5187. doi: 10.1007/s12325-023-02649-0. Epub 2023 Sep 26. Adv Ther. 2023. PMID: 37751025 Free PMC article.

3

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study.

Keith PK, Cowan J, Kanani A, Kim H, Lacuesta G, Lee JK, Chen J, Park M, Gladiator A. Keith PK, et al. Among authors: park m. Allergy Asthma Clin Immunol. 2022 Aug 7;18(1):70. doi: 10.1186/s13223-022-00709-8. Allergy Asthma Clin Immunol. 2022. PMID: 35934726 Free PMC article.

4

Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.

Rosenbach K, Park M, Sanchirico M, Nwose O, Paris K. Rosenbach K, et al. Among authors: park m. J Clin Immunol. 2023 Jul;43(5):912-920. doi: 10.1007/s10875-023-01436-4. Epub 2023 Feb 21. J Clin Immunol. 2023. PMID: 36809598 Free PMC article.

5

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study.

Keith PK, Cowan J, Kanani A, Kim H, Lacuesta G, Lee JK, Chen J, Park M, Gladiator A. Keith PK, et al. Among authors: park m. Allergy Asthma Clin Immunol. 2023 Jun 23;19(1):54. doi: 10.1186/s13223-023-00805-3. Allergy Asthma Clin Immunol. 2023. PMID: 37353830 Free PMC article. No abstract available.

6

Systematic review of real-world persistence and adherence in subcutaneous allergen immunotherapy.

Park MJ, Kapoor S, Yi J, Hura N, Lin SY. Park MJ, et al. Int Forum Allergy Rhinol. 2023 Mar;13(3):255-264. doi: 10.1002/alr.23078. Epub 2022 Oct 13. Int Forum Allergy Rhinol. 2023. PMID: 36083799 Review.

7

Sublingual immunotherapy persistence and adherence in real-world settings: A systematic review.

Park M, Kapoor S, Yi J, Hura N, Lin SY. Park M, et al. Int Forum Allergy Rhinol. 2023 May;13(5):924-941. doi: 10.1002/alr.23086. Epub 2022 Sep 21. Int Forum Allergy Rhinol. 2023. PMID: 36083179 Review.

8

Association between insulin-associated gene polymorphisms and new-onset diabetes mellitus in statin-treated patients.

Park M, Kim JS, Park YA, Lee DH, Choi SA, Chang Y, Song TJ, Gwak HS, Yee J. Park M, et al. Eur J Clin Invest. 2024 Nov 30:e14366. doi: 10.1111/eci.14366. Online ahead of print. Eur J Clin Invest. 2024. PMID: 39614667

9

Rare Case of Germline GATA2-Deficiency With Merkel Cell Carcinoma and Acute Myeloid Leukemia.

Yu S, Park MS, Kim GY, Cho J, Jung CW, Kim HJ, Kim HY. Yu S, et al. Among authors: park ms. Cancer Rep (Hoboken). 2024 Dec;7(12):e70068. doi: 10.1002/cnr2.70068. Cancer Rep (Hoboken). 2024. PMID: 39614632 Free PMC article.

10

Mastering seismic time series response predictions using an attention-Mamba transformer model for bridge bearings and piers across varied testing conditions.

Yazdanpanah O, Park M, Chang M, Chae Y. Yazdanpanah O, et al. Among authors: park m. Sci Rep. 2024 Nov 29;14(1):29751. doi: 10.1038/s41598-024-79195-4. Sci Rep. 2024. PMID: 39613766 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,517 results

Search Page

Filters